Clinical Edge Journal Scan

Risk for major ischemic events in BC patients receiving radiotherapy


 

Key clinical point: Patients with breast cancer (BC), particularly those with left-sided BC who underwent radiotherapy, faced the risk of developing major ischemic events.

Major finding: At a median follow-up of 7.9 years, the incidence of a major ischemic event was reported in 4.1% of patients, with the incidence rate being significantly higher in patients with left-sided vs right-sided BC (P = .044). The risk for major ischemic events increased by 6.2% per Gy increase in the mean heart dose (hazard ratio 1.062; P = .012).

Study details: This retrospective study included 2158 women with BC who received adjuvant radiotherapy.

Disclosures: This study was supported by the Taipei Veterans General Hospital, Taiwan, and other sources. The authors declared no conflicts of interest.

Source: Lai TY et al. Association of radiation dose to cardiac substructures with major ischaemic events following breast cancer radiotherapy. Eur Heart J. 2023 (Aug 16). doi: 10.1093/eurheartj/ehad462

Recommended Reading

Mammography breast density reporting: What it means for clinicians
MDedge Hematology and Oncology
AI mammogram screening is equivalent to human readers
MDedge Hematology and Oncology
Exercise tied to lower mortality risk across cancer types
MDedge Hematology and Oncology
Luminal A BC patients can skip radiotherapy after breast-conserving surgery
MDedge Hematology and Oncology
Giredestrant shows promising outcomes in HR+ /HER2− BC in phase 2 study
MDedge Hematology and Oncology
Metastatic BC: Meaningful clinical benefit with trifluridine/tipiracil in phase 2 study
MDedge Hematology and Oncology
TNBC: Greater efficacy of neoadjuvant apatinib + dose-dense paclitaxel + carboplatin vs dose-dense paclitaxel + carboplatin
MDedge Hematology and Oncology
High temporal and spatial resolution improves BC detection in women with high background parenchymal enhancement
MDedge Hematology and Oncology
BRCA-altered TNBC: High-dose alkylating chemotherapy fails to show improvement in phase 3 study
MDedge Hematology and Oncology
Adjuvant ET lowers distant metastases risk in ER+ /HER2− T1a/bN0M0 BC
MDedge Hematology and Oncology